Bio-Rad Laboratories’ stocks have witnessed a series of ups and downs over the year. The stocks recently
reached a new 52-week high due to robust growth and stronger operational gains, which boosted the company's relative price strength. Despite this positive surge, the stock then declined by 4.6%, resulting in
a 58% loss for shareholders. Despite these fluctuations, multiple firms and capital advisories have invested heavily in Bio-Rad, such as Rovin Capital UT ADV and Kornitzer Capital Management Inc. However, questions around Bio-Rad’s underperformance in the healthcare sector persist. Following the earnings call, Bio-Rad reported solid Q3 growth, with net income surges pushing the shares up. Large stakeholders such as Veritas Asset Management and DekaBank Deutsche Girozentrale continue to hold substantial shares. Notwithstanding the losses, it seems Citi is confident about Bio-Rad's progress,
upgrading it to a 'Buy' rating and raising the price target. Bio-Rad’s leadership has also seen changes with a new President and COO being appointed, while Q3 earnings and revenues
surpass estimates, pushing the stock up aftermarket.
Bio-Rad Laboratories Stocks News Analytics from Sun, 07 Jun 2015 03:49:27 GMT to Sat, 09 Nov 2024 23:44:49 GMT -
Rating 0
- Innovation 4
- Information 8
- Rumor -5
